Company profile: Biomind Labs
1.1 - Company Overview
Company description
- Provider of pharmaceutical development for neurological and psychiatric disorders, advancing candidates including BMND01 for treatment-resistant depression, BMND03 for addictive disorders, BMND07 for major depressive disorder, BMND09 for Parkinson’s disease, BMND08 for depression and anxiety in Alzheimer’s disease, and Triptax™, a new chemical entity for treatment-resistant depression with FDA IND clearance.
Products and services
- Triptax™: A new chemical entity targeting treatment-resistant depression, with FDA investigational new drug clearance for this indication, representing Biomind Labs’ IND-cleared antidepressant candidate
- BMND08: A candidate for treating depression and anxiety in Alzheimer’s disease, currently in clinical trials, positioned as a clinical-stage neuropsychiatric therapy within Biomind Labs’ pipeline
- BMND01: A pharmaceutical candidate developed for treatment-resistant depression, categorized as an antidepressant candidate within Biomind Labs’ neurology and psychiatric drug-development focus
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Biomind Labs
Percuro
HQ: Brazil
Website
- Description: Provider of clinical research and health services, committed to the provision of effective treatments in a safe and supportive environment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Percuro company profile →
Pyramid Laboratories
HQ: United States
Website
- Description: Provider of contract parenteral drug product manufacturing and analytical services for the pharmaceutical and biotechnology industries, including aseptic vial and syringe filling, lyophilization, formulation and process development, clinical supply manufacturing, commercial fill/finish, and labeling, storage, and global distribution.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Pyramid Laboratories company profile →
Synteract HCR
HQ: United States
Website
- Description: Provider of global full-service contract research organization support for biotechnology, medical device, and pharmaceutical companies across all phases of clinical development, delivering customized Phase I–IV services collaboratively and cost effectively.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synteract HCR company profile →
Appletree CI
HQ: Switzerland
Website
- Description: Provider of specialized CRO and CSO services in ophthalmology and medical device investigations, offering global regulatory affairs and end-to-end clinical development solutions, flexible functional service outsourcing, real-world evidence and virtual studies, advisory and talent support, and strategic resourcing across 11 European nations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Appletree CI company profile →
Jennewein Biotech
HQ: Germany
Website
- Description: Provider of industrial biotechnology solutions specializing in developing processes for the identification, characterization, and production of scarce, functional monosaccharides and oligosaccharides, with a focus on sugar molecules offering attractive health benefits.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Jennewein Biotech company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Biomind Labs
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Biomind Labs
2.2 - Growth funds investing in similar companies to Biomind Labs
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Biomind Labs
4.2 - Public trading comparable groups for Biomind Labs
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →